

Mnemonic Distinguishes Depression, Dementia

BY MARY ELLEN SCHNEIDER
New York Bureau

HOLLYWOOD, FLA. — Common psychiatric disorders such as depression and dementia can be hard to distinguish in elderly patients, but there are some simple techniques that physicians can use to draw out the differences, Dr. Kevin Gray said at the annual symposium of the American Medical Director's Association.

"Dementia and depression can occur together or separately," said Dr. Gray of the department of neurology at the University of Texas Southwestern Medical Center at Dallas.

One of the reasons that there is so much confusion about what is dementia and what is depression is that the symptoms can overlap to some degree, he said.

The mnemonic device SIG-E-CAPS represents the diagnostic elements of major depressive disorder. Also look for helplessness and hopelessness.

In a typical case, a family member will describe a patient's passivity, weight changes, sleep disturbances, sweet tooth, restlessness, declines in cognition, or lack of interest in favorite activities. All of these symptoms could be depression, he said.

The key elements in distinguishing between depression and dementia in that type of patient include the presence of true suicidality or feelings of worthlessness and guilt. These symptoms are characteristic of depressive syndrome but are rare in dementias such as Alzheimer's disease, he said.

When eliciting depression symptoms, Dr. Gray suggested using the mnemonic device SIG-E-CAPS, which represents the diagnostic elements of major depressive disorder: sleep, interest, guilt, energy, concentration, appetite, psychomotor activity, and suicidal ideation. Also look for changes in self-attitude, including helplessness, hopelessness, and worthlessness, he said.

It can be misleading to focus too much on some of the somatic issues related to depression, such as sleep problems and appetite, because these can be affected by so many of the conditions common in older adults, such as chronic pain, he said.

"The key is to tap into changes in self-attitude," Dr. Gray said.

There are a variety of scales available and he uses the five-item version of the Short Geriatric Depression Scale since it can be performed quickly.

When depression is nonresponsive to treatment, confirm or refine your diagnosis, Dr. Gray advised. You could be dealing with patients with an underlying delirium or dementia, early parkinsonism, involuntary emotional expression disorder, or apathy syndromes. Performing a mental status exam in these patients is critical, he said.

Physicians also may run into difficulties

distinguishing the symptoms of Alzheimer's disease from other types of dementia. Alzheimer's disease is characterized by an inability to learn new information that is in many ways unique, Dr. Gray said.

Physicians can demonstrate that a patient is "losing information" without having to have a PET scanner in the office, Dr. Gray said.

Instead, try a three-word cued recall test with patients. Ask the patient to try to

remember three words, such as Oldsmobile, carrot, and piano. Wait a few minutes and ask the patient to try to recall the words. If they can't recall the words spontaneously, give them clues or choices to prompt them.

Impaired recall by itself enough isn't enough to indicate Alzheimer's disease, Dr. Gray said.

Many individuals without dementia of any kind can be forgetful.

However, the cued recall test, which in-

cludes providing hints to the patient, can help demonstrate whether the new information is available to be recalled.

Beware of making a diagnosis of Alzheimer's disease if memory loss is not a major feature, the recognition memory is intact, and there are early personality changes, Dr. Gray said.

Other dementias are generally characterized by executive impairment, mood and motor symptoms, and other impairments such as slow processing. ■

You can prescribe Rozerem for as long as you need to*



Clinical studies show no evidence of potential abuse, dependence, or withdrawal†

- **First and only**—nonscheduled prescription insomnia medication...not a controlled substance and can be prescribed for long-term use¹
- **First and only**—prescription insomnia medication that targets the normal sleep-wake cycle¹
- **First and only**—prescription insomnia medication with no evidence of abuse potential in clinical studies¹
- **First and only**—prescription insomnia medication that does not promote sleep by CNS depression¹
- **One simple 8-mg dose**¹

†Rozerem is not a controlled substance. A clinical abuse liability study showed no differences indicative of abuse potential between Rozerem and placebo at doses up to 20 times the recommended dose (N=14). Three 35-day insomnia studies showed no evidence of rebound insomnia or withdrawal symptoms with Rozerem compared to placebo (N=2082).^{1,2}

*Rozerem™ (ramelteon) is indicated for the treatment of insomnia characterized by difficulty with sleep onset. Rozerem can be prescribed for long-term use.

Important safety information

Rozerem should not be used in patients with hypersensitivity to any components of the formulation, severe hepatic impairment, or in combination with fluvoxamine. Failure of insomnia to remit after a reasonable period of time should be medically evaluated, as this may be the result of an unrecognized underlying medical disorder. Hypnotics should be administered with caution to patients exhibiting signs and symptoms of depression. Rozerem has not been studied in patients with severe sleep apnea, severe COPD, or in children or adolescents. The effects in these populations are unknown. Avoid taking Rozerem with alcohol. Rozerem has been associated with decreased testosterone levels and increased prolactin levels. Health professionals should be mindful of any unexplained symptoms possibly associated with such changes in these hormone levels. Rozerem should not be taken with or immediately after a high-fat meal. Rozerem should be taken within 30 minutes before going to bed and activities confined to preparing for bed. The most common adverse events seen with Rozerem that had at least a 2% incidence difference from placebo were somnolence, dizziness, and fatigue.

Please visit www.rozerem.com

Please see adjacent Brief Summary of Prescribing Information.

Rozerem™
ramelteon 8-mg tablets

Proven for sleep.
Nonscheduled for added safety.